Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A double-blind, double dummy, randomized, parallel group, multi-center, phase III study to evaluate the efficacy and safety of TAK-475 [lapaquistat] alone and TAK-475 administered in combination with ezetimibe versus ezetimibe alone in subjects with primary dyslipidemia.

Next Previous
X
Search
Trial Profile

A double-blind, double dummy, randomized, parallel group, multi-center, phase III study to evaluate the efficacy and safety of TAK-475 [lapaquistat] alone and TAK-475 administered in combination with ezetimibe versus ezetimibe alone in subjects with primary dyslipidemia.

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 21 Jan 2022

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Lapaquistat (Primary) ; Ezetimibe
  • Indications Hypercholesterolaemia
  • Focus Registrational; Therapeutic Use
  • Sponsors Takeda; Takeda Europe Research & Development Centre; Takeda Global Research and Development Center

    • Most Recent Events

    • 28 Mar 2008 Status changed from in progress to discontinued. According to a Takeda media release, development of lapaquistat is being discontinued.
    • 07 Dec 2006 New trial record.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top